Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MErCuRIC1: Binimetinib/PD-0325901 + Crizotinib in CRC
NCT02510001Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Nov 2014
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of binimetinib and crizotinib in colorectal cancer (CRC) (3 arms), sponsored by University of Oxford. Primary endpoints: Maximal Tolerated Dose and Clinical Response up to 12 months. Started Nov 2014; status: completed.
02
Drugs
binimetinibcrizotinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02510001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02510001.